Sorafenib-induced Pancreatic Pseudocyst in a Patient with Advanced Hepatocellular Carcinoma: a Rare Adverse Event
- Author:
Dae ha KIM
1
;
Minkoo KIM
;
Hyung Joon YIM
;
Sang Jun SUH
;
Young Kul JUNG
Author Information
- Publication Type:Case Report
- Keywords: Advanced hepatocellular carcinoma; Sorafenib; Adverse event; Pancreatic pseudocyst; Pancreatitis
- MeSH: Abdominal Pain; Amylases; Appetite; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; Drug Therapy; Endoscopy, Digestive System; Humans; Lipase; Nausea; Pancreatic Pseudocyst; Pancreatitis; Tail
- From:Journal of Liver Cancer 2019;19(2):154-158
- CountryRepublic of Korea
- Language:English
- Abstract: A 54-year old man diagnosed with advanced hepatocellular carcinoma began treatment with sorafenib. After 3 weeks of treatment, he complained of abdominal pain and nausea. Abdominal sonography showed multiple hepatic lesions only. Serum amylase and lipase levels were 35 U/L and 191 U/L, respectively. The patient was diagnosed with sorafenib-induced acute pancreatitis. After 10 days of discontinuing sorafenib he still complained of nausea and loss of appetite. Esophagogastroduodenoscopy showed a large bulging lesion, which was suspected to cause extrinsic compression on the high body of the gastric anterior wall. Computed tomography scan revealed a cystic lesion, 8.3 cm in size, in the pancreatic tail, suggesting a pancreatic pseudocyst. After the withdrawal of sorafenib, systemic chemotherapy with Adriamycin and cisplatin was administered. Four months after the discontinuation of sorafenib, the size of the pancreatic pseudocyst decreased from 8.3 cm to 3 cm. The patient's symptoms were also relieved.
